Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $52.7552W HIGH $93.42
Volume
3.36 M
Value Traded
249.86 M
Short % Float
12.31%
-3.29%Week
-14.51%1 Month
-24.28%3 Month
-12.8%6 Month
+17.55%5 Year
+125.81%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
12.71 B
EPS (TTM)
-3.59
P/E Ratio
-
Ent. Value
14.65 B
Total Shares
195.56 M
Float Shares
175.06 M
Insiders
10.45%
Institutions
91.32%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
BBIO Catalyst Timeline
Dated clinical, regulatory and corporate events for BridgeBio Pharma, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for BridgeBio Pharma, Inc.
690Total events
25Upcoming
208Tier-1 (high impact)
2019 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Timing GuidancePresentation
Nationwide ATTR-CM education effort begins with October 6 YouTube premiere
transthyretin amyloid cardiomyopathy (ATTR-CM)source ↗
▲FDA Filing AcceptedInfigratinibApprovedRegulatory Filing
FDA accepts NDA for oral infigratinib in children with achondroplasia for Priority Review
achondroplasiasource ↗
▲Priority ReviewInfigratinibApprovedRegulatory Filing
FDA grants Priority Review for oral infigratinib NDA in achondroplasia
achondroplasiasource ↗
▲Biomarker DataBBP-418FiledClinical Data
BBP-418 increased mean glycosylated αDG to asymptomatic heterozygous FKRP carrier levels by Month 3, sustained through Month 12
Limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) (FKRP-related)source ↗
▲Interim Efficacy DataBBP-418FiledClinical Data
BBP-418 normalized HS troponin I in 100% of treated participants with elevated baseline levels vs 40% placebo (p=0.0248)
Limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) (FKRP-related)source ↗
▲Oral PresentationBBP-418FiledPresentation
BBP-418 FORTIFY 12-month interim cardiac data presented orally at World Muscle Society Congress
Limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) (FKRP-related)source ↗
▲Interim AnalysisBBP-418FiledTrial
12-month interim analysis of FORTIFY presented at WMS 2026
Limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) (FKRP-related)source ↗
▲Interim AnalysisBBP-418FiledTrial
FORTIFY Phase 3 12-month interim analysis of BBP-418
Limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) (FKRP-related)source ↗
◆Poster PresentationInfigratinibApprovedPresentation
Poster on PROPEL Infant and Toddler study design and enrollment at ESPE 2026
achondroplasiasource ↗
◆Poster PresentationPresentation
ePoster on qualitative research on hypochondroplasia impacts at ESPE 2026
hypochondroplasiasource ↗
◆Poster PresentationAcoramidisApprovedPresentation
Poster: Long-term Improvement in Myocardial Structure and Function in Patients with ATTR-CM Treated with Acoramidis
transthyretin amyloid cardiomyopathy (ATTR-CM)source ↗
●Equity OfferingCorporate
Pricing of secondary offering of 5,000,000 shares by KKR Genetic Disorder L.P.
▼Equity OfferingCorporate
Launch of secondary public offering of 5,000,000 shares by KKR Genetic Disorder L.P.
◆Oral PresentationInfigratinibApprovedPresentation
Oral presentation on health-related quality of life from PROPEL study at ICCBH 2026
achondroplasiasource ↗
◆Poster PresentationPresentation
Poster on ACCEL observational study in hypochondroplasia at ICCBH 2026
hypochondroplasiasource ↗
◆Late-BreakerInfigratinibApprovedPresentation
Late-breaking oral presentation of additional positive data from PROPEL 3 at ICCBH 2026
achondroplasiasource ↗
◆Poster PresentationInfigratinibApprovedPresentation
Poster on design of PROPEL Infant and Toddler study at ICCBH 2026
achondroplasiasource ↗
▲FDA Filing AcceptedBBP-418FiledRegulatory Filing
FDA accepted NDA for BBP-418 with Priority Review
LGMD2I/R9source ↗
▲AdCom CancelledBBP-418FiledAdvisory Committee
FDA not planning to hold advisory committee meeting
LGMD2I/R9source ↗
▲Priority ReviewBBP-418FiledRegulatory Filing
Priority Review granted for BBP-418 NDA
LGMD2I/R9source ↗
◆Oral PresentationEncaleretFiledPresentation
Primary results from Phase 3 CALIBRATE trial of encaleret in ADH1 presented at 2026 ECE
autosomal dominant hypocalcemia type 1 (ADH1)source ↗
●NDA SubmissionEncaleretFiledRegulatory Filing
NDA submission to FDA for encaleret in ADH1
autosomal dominant hypocalcemia type 1 (ADH1)source ↗
▲Oral PresentationAcoramidisApprovedPresentation
Acoramidis reduces sTTR variability and outpatient worsening heart failure at Heart Failure 2026
transthyretin amyloid cardiomyopathy (ATTR-CM)source ↗
▲Poster PresentationAcoramidisApprovedPresentation
Effect of acoramidis on improvement or maintenance of health status at Heart Failure 2026
transthyretin amyloid cardiomyopathy (ATTR-CM)source ↗
◆Poster PresentationPresentation
Baseline quality of life measures in CLARIFY disease monitoring study presented at 2026 ECE
autosomal dominant hypocalcemia type 1 and type 2source ↗
●Quarterly UpdateCorporate
BridgeBio launches national health education campaign 'Don't Pass On Your Heart Health' featuring Morgan Freeman and Howard H. White
◆Late-BreakerAcoramidisApprovedPresentation
Long-Term Survival Benefits and Disease Stabilization with Acoramidis in Patients with ATTR-CM
ATTR-CMsource ↗
◆Late-BreakerBBP-418FiledPresentation
Late-breaking oral presentation of additional data from interim analysis of FORTIFY trial
limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9)source ↗
◆Poster PresentationBBP-418FiledPresentation
Poster: The Journey of BBP-418: From LGMD2I/R9 Disease Pathophysiology to Registrational Clinical Trials
limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9)source ↗
▲Oral PresentationBBP-418FiledPresentation
Late-breaking oral presentation at 2026 MDA Clinical and Scientific Conference
LGMD2I/R9source ↗
▲Enrollment CompleteInfigratinibApprovedTrial
Phase 2 portion enrollment completed
hypochondroplasiasource ↗
▲Topline ReadoutBBP-418FiledClinical Data
Positive interim analysis topline results released
LGMD2I/R9source ↗
▲Topline ReadoutInfigratinibApprovedClinical Data
Positive topline results released
achondroplasiasource ↗
●End Of Phase 2 MeetingEncaleretFiledFDA Meeting
FDA End of Phase 2 interaction completed
chronic hypoparathyroidismsource ↗
▲Primary Endpoint MetBBP-418FiledClinical Data
FORTIFY interim analysis met primary and secondary endpoints
LGMD2I R9source ↗
▲Primary Endpoint MetEncaleretFiledClinical Data
CALIBRATE Phase 3 met primary and key secondary endpoints
ADH1source ↗
▲Primary Endpoint MetInfigratinibApprovedClinical Data
PROPEL 3 met primary endpoint (AHV at Week 52, p<0.0001)
achondroplasiasource ↗
●Trial InitiationEncaleretFiledTrial
CALIBRATE-PEDS registrational Phase 2/3 study initiated
ADH1 (pediatric)source ↗
▲Topline ReadoutInfigratinibApprovedClinical Data
Positive Phase 3 topline results for oral infigratinib in achondroplasia
achondroplasiasource ↗
▲Primary Endpoint MetInfigratinibApprovedClinical Data
PROPEL 3 met primary endpoint of change from baseline in AHV at Week 52
achondroplasiasource ↗
◆Trial InitiationInfigratinibApprovedTrial
Ongoing clinical trial of infigratinib in newborn to <3 year old age groups
achondroplasiasource ↗
◆Oral PresentationInfigratinibApprovedPresentation
Investor call to discuss PROPEL 3 results
achondroplasiasource ↗
Past FDA Catalysts and PDUFA Decisions
How BBIO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-08-28 | Attruby (acoramidis) | Phase 3 data presentation | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C50 / 100
Pipeline Score
$732M
Pipeline Value
$2.8B
Commercial Value
Richly Valued
Valuation Signal
9
Drugs Scored
0.1x
rNPV / MCap
Top 17%
Mid Cap(rank 113 of 658)
Percentile Rank
BridgeBio Pharma, Inc. carries a moderate pipeline score (50/100), with $861M risk-adjusted pipeline value, led by BBP-418 in LGMD2I (Phase 2).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $713.1M x 4.0 = $2.8B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Attruby | $657M | $111M | +491.4% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BBP-418 Small moleculeNCT05775848 | Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I) | Phase 3 | ACTIVE NOT_RECRUITING | 188 | Jul 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every BBIO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| BBP-418 PriorityFast TrackAccelerated+2 | limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) | Phase 3 | 2026-10-05 | 100% of treated individuals normalized HS troponin I levels; 54% showed stable or improved left ventricular ejection fraction (LVEF); HS troponin I declined more with BBP-418 than placebo (LS mean difference -17.8 ng/L; 95% CI: -35.1 to -0.5; p=0.0443); 54% of BBP-418-treated individuals had stable or improved LVEF at Month 12 versus 25% in the placebo arm (p=0.0262)Read More | BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected LevelsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Kumar NeilDirector, Officer (Chief Executive Officer) | Sell | -8,721 496,965 held | $69.01 | 09/17/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BBIO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 2.5 % (-62.1 %) | 115.31 M | 1.55 M | -55.1% ( -1.90 M) |
BBIO Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-02-19 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BBIO ranks across every disease it competes in
Competitive Position is a premium feature
See how BBIO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBBIO News
BBIO▼ -2.2%today
BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026
BridgeBio Pharma will present new data on acoramidis at the HFSA Annual Scientific Meeting 2026. The presentations will include one oral presentation, three rapid-fire oral presentations, and six poster presentations focused on the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). Acoramidis is highlighted as a first-line treatment option, with data supporting its clinical profile and effectiveness.
Read more →BBIO▼ -2.2%today
BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting
BridgeBio Pharma will present additional findings from the Phase 3 CALIBRATE trial of encaleret for autosomal dominant hypocalcemia type 1 (ADH1) at the ASBMR 2026 Annual Meeting. The presentations will include patient-reported outcomes and bone turnover effects. Additionally, data on genetic testing initiatives and safety profiles in children with achondroplasia will be shared.
Read more →BBIO▼ -2.2%today
BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia
BridgeBio announced that the FDA has accepted its New Drug Application for oral infigratinib, a potential first oral treatment for children with achondroplasia, with a target action date of February 4, 2027. The PROPEL 3 trial demonstrated significant efficacy, including the largest annualized height velocity reported in a Phase 3 study. The company is prepared for a U.S. launch upon approval and plans to submit a Marketing Authorization Application to the EMA.
Read more →BBIO▼ -2.2%today
BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day
BridgeBio Pharma has launched a nationwide education initiative to raise awareness about transthyretin amyloid cardiomyopathy (ATTR-CM), particularly among Black Americans who are at higher risk. The campaign kicks off with a YouTube premiere on October 6, featuring discussions led by notable figures in health and culture. The initiative aims to improve recognition and understanding of ATTR-CM, which is often misdiagnosed or overlooked.
Read more →BBIOBBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels
BridgeBio Pharma presented promising data on BBP-418 during the Phase 3 FORTIFY trial for LGMD2I/R9. At the 12-month interim analysis, 100% of treated individuals normalized HS troponin I levels, and 54% showed stable or improved left ventricular ejection fraction (LVEF). BBP-418 is under FDA Priority Review with a target action date of November 27, 2026, and may become the first approved therapy for this condition.
Read more →BBIO▼ -5.1%on this news
Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening
Acoramidis has demonstrated a statistically significant benefit over tafamidis in reducing clinical worsening events in patients with ATTR-CM, according to a recent study. The findings indicate a 34% reduction in composite clinical worsening events and a 43% reduction in diuretic intensification. These results highlight acoramidis's potential as a frontline treatment option. Further studies are planned to validate these findings.
Read more →BBIOBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma announced the approval of equity grants to 36 new employees, totaling 63,009 shares of common stock. These grants are part of the company's strategy to attract talent and are structured to vest over time, promoting long-term employment. This initiative aligns with Nasdaq Listing Rule 5635(c)(4) and reflects BridgeBio's commitment to developing treatments for genetic conditions.
Read more →BBIOOral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial
The Phase 3 PROPEL 3 trial of oral infigratinib demonstrated meaningful benefits for children with achondroplasia, including stabilization of sleep apnea and reduced ear infections. The treatment showed sustained improvements in growth and body proportionality over three years, with a favorable safety profile. BridgeBio has submitted an NDA to the FDA, anticipating a U.S. launch in mid-2027.
Read more →BBIOBridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026
BridgeBio Pharma will present new findings on oral infigratinib's effects on achondroplasia at the Annual ESPE Meeting 2026. The late-breaking oral presentation will focus on the results from the PROPEL 3 study, alongside additional posters detailing longer-term data. This research aims to address critical medical complications associated with achondroplasia and hypochondroplasia.
Read more →BBIOBridgeBio to Participate in September Investor Conferences
BridgeBio Pharma, Inc. announced its participation in several upcoming healthcare investor conferences in September 2026. The management team will engage in fireside chats at notable events, including the Wells Fargo Healthcare Conference and the Morgan Stanley Global Healthcare Conference. Live webcasts of these presentations will be accessible on the company's website.
Read more →BBIOBridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
BridgeBio Pharma has entered a voluntary agreement with the U.S. government to enhance access to its medicines and reduce costs for American patients, particularly those on Medicaid. The agreement aims to maintain innovation in rare disease treatments while ensuring affordability. BridgeBio's Attruby will remain available through Medicare without future pricing mandates, and the company continues to support patients through its ForgingBridges program.
Read more →BBIOAcoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM
Acoramidis, a treatment for transthyretin amyloid cardiomyopathy (ATTR-CM), has shown promising results in reversing cardiac disease progression and improving patient outcomes. In a Phase 3 study, patients treated with acoramidis experienced significant increases in days alive and free from hospitalization. The therapy demonstrated long-term efficacy and safety across different genetic subgroups, marking a potential shift in treatment for ATTR-CM.
Read more →BBIOBridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM
BridgeBio Pharma has initiated the ASCEND-ATTR study, dosing its first participant to evaluate the long-term effects of acoramidis on cardiac structure and function in patients with ATTR-CM. This Phase 3b/4 study aims to determine if acoramidis can lead to sustained improvements in cardiac health, building on previous positive findings from the ATTRibute-CM CMR substudy. The study will enroll approximately 150 participants and utilize advanced imaging techniques to assess treatment efficacy over 36 months.
Read more →BBIOBridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026
BridgeBio Pharma will present new data on acoramidis for ATTR-CM at the ESC Congress 2026. The findings highlight acoramidis as a first-line treatment, demonstrating significant clinical benefits. Presentations include results on survival benefits and quality of life improvements, further establishing the drug's efficacy in managing this condition.
Read more →BBIOBridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base
BridgeBio Pharma has announced the pricing of an oversubscribed secondary offering of 5 million shares, which will be sold by KKR Genetic Disorder L.P. The company will not receive any proceeds from this offering, which is set to close on August 17, 2026. This move aims to enhance the quality of its shareholder base.
Read more →BBIOBridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder
BridgeBio Pharma has announced a secondary public offering of 5,000,000 shares of common stock on behalf of KKR Genetic Disorder L.P. The company will not sell any shares or receive proceeds from this offering. The offering is subject to market conditions, and the final terms will be disclosed in a prospectus supplement filed with the SEC.
Read more →BBIOBridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET
BridgeBio Pharma, Inc. will announce its second quarter 2026 financial results and business updates on August 10, 2026. The company will host a conference call at 4:30 pm ET to discuss these results. Interested parties can access the live webcast through the company's website, with a replay available for 30 days post-event.
Read more →BBIOBridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026
BridgeBio Pharma will present positive results from the Phase 3 PROPEL 3 trial of oral infigratinib for children with achondroplasia at the ICCBH 2026. The presentation will include a late-breaking oral session and several posters highlighting various aspects of achondroplasia and related conditions. The event will take place in Montreal from June 27-30, 2026.
Read more →About BridgeBio Pharma, Inc.
Headquarters3160 PORTER DR., PALO ALTO, CA, 94304
Founded2015
BIOPHARMAWATCH ELITE PLUS
Trade the next BBIO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime